Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Walgreens Boots Alliance Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Active Flu Season Boosts Walgreen's January Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 07:36pm CEST

Walgreen Co. (>> Walgreen Company) posted its first monthly same-store sales gain in a year in January, aided by an active flu season and firmer prescription orders stemming from the resolution of a contract dispute with a major pharmacy-benefits manager.

The 3.7% increase in same-store sales in January came above the projected 1.5% increase, according to analysts surveyed by Thomson Reuters.

Results last year were hurt by a rate contract dispute with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that led millions to transfer their prescriptions to rival pharmacies. But since Walgreen and Express Scripts entered a new multiyear agreement that began in September, millions have returned to the fold.

The loss of the Express Scripts customers, as well as higher demand for lower-priced generic drugs, hurt Walgreen's same-store sales throughout 2012. In 2012, January's same-store sales dropped 4.6%.

Walgreen has also successfully courted some customers it had lost in the dispute and hopes to win back more, gains executives expect will be reflected in many of 2013's monthly sales reports. In January, pharmacy sales grew 8.7% and same-store pharmacy sales increased 6.2%, compared with an expected 2.4% jump. Prescriptions filled at comparable stores soared 14%.

Overall, total sales in January grew 6.3% to $6.15 billion from a year ago. Front-end sales were up 1.3%, while same-store front-end sales slid 0.4%, compared with expectations of a 0.5% drop.

Drugstore front-end sales have been helped by a nasty flu season, bolstering traffic and demand for prescriptions and over-the-counter treatments. Walgreen, which provides more flu vaccines in the U.S. than any other retailer, said it has administered 6.9 million flu vaccines so far this season, far above last year's 5.5 million.

But drugstore-retailer results have been stung by increasing demand for generic drugs, which Walgreen said hurt January's pharmacy same-store sales by six percentage points. Strong demand for those drugs products a mixed effect because copycat drugs carry higher margins than branded products but command lower prices, hurting same-store sales.

Last week, Rite Aid Corp. (>> Rite Aid Corporation) reported January same-store sales were up 0.3%, as a very active flu season helped offset the pressure from generics. CVS Caremark Corp. (>> CVS Caremark Corporation), which doesn't report monthly sales data, has already warned same-store sales in the first quarter would be lower. The company's full fourth-quarter results are due on Wednesday.

Walgreen's shares were inactive at $40.01 in premarket trading.

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WALGREENS BOOTS ALLIANCE I
06/23 INTERRA RESOURCES : Walgreens to open niche pharmacy in downtown Akron
06/22DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens to Settle -- WSJ
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit--Upd..
06/21 WALGREENS BOOTS ALLIANCE : Settles Suit with Tech Firm
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit
06/19 WALGREENS : and Greater Than AIDS Team Up with Health Departments and Community ..
06/03 Dollar Express sues Dollar Tree for driving it out of business
06/02 WALGREENS BOOTS ALLIANCE, INC. : Triggering Events That Accelerate or Increase a..
05/30 WALGREENS BOOTS ALLIANCE : Schedules Fiscal 2017 Third Quarter Earnings Announce..
05/30 WALGREENS BOOTS ALLIANCE : Flu Index Shows Top States, Markets for Flu Activity ..
More news
Sector news : Drug Retailers - NEC
06/21 STADA ARZNEIMITTEL : Low acceptances leave Stada bid down to the wire
06/20 U.S. Supreme Court again limits where companies can be sued
05/17DJCVS HEALTH : Why Your Pharmacy May Be Texting You -- WSJ
05/15 SHANGHAI PHARMACEUTICALS : Advent, Shanghai Pharma have not approached Stada - s..
05/02 CVS HEALTH : profit beats as pharmacy margins rise
More sector news : Drug Retailers - NEC
Advertisement
Financials ($)
Sales 2017 117 145 M
EBIT 2017 7 293 M
Net income 2017 4 689 M
Debt 2017 10 364 M
Yield 2017 1,98%
P/E ratio 2017 18,14
P/E ratio 2018 15,98
EV / Sales 2017 0,79x
EV / Sales 2018 0,73x
Capitalization 82 520 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,4 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefano Pessina Executive Vice Chairman & Chief Executive Officer
James A. Skinner Executive Chairman
Ornella Barra Co-Chief Operating Officer
Alexander W. Gourlay Co-Chief Operating Officer
George Rollo Fairweather Global Chief Financial Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
WALGREENS BOOTS ALLIAN..82 520
WALGREENS BOOTS ALLIAN..-7.76%82 520
CVS HEALTH-1.90%78 865
EXPRESS SCRIPTS HOLDIN..-5.19%39 152
MCKESSON CORPORATION18.88%35 305
CARDINAL HEALTH INC9.42%25 170
More Results